Sökning: "IGF-1R"
Visar resultat 21 - 25 av 44 avhandlingar innehållade ordet IGF-1R.
21. Role of dolichyl phosphate, N-linked glycosylation and cell membrane expression of insulin-like growth factor-1 receptor in maintenance of malignant cell growth
Sammanfattning : Several studies have demonstrated that mevalonate (MVA) synthesis is required for cell proliferation. The mechanisms underlying MVA-regulated cell growth are still not fully understood. One conceivable mechanism for MVA-dependent cell growth is N-linked glycosylation of growth regulatory proteins. LÄS MER
22. Importance of insulin-like growth factor-1 receptor and EWS/FLI-1 fusion protein in growth and survival of two different types of neuroectodermal tumor cells
Sammanfattning : Treatment with comparatively low doses of the 3-hydroxy-3-metylglutaryl coenzyme A (HMG-CoA) reductase inhibitor lovastatin caused growth arrest in both melanoma cells and Ewing's sarcoma (ES) cells. In melanoma cells growth inhibition was correlated with a drastic decrease in N-linked glycosylation of the insulin-like growth factor-1 receptor (IGF-1R), which in turn was followed by a decreased expression of IGF-1 binding sites at the cell surface. LÄS MER
23. Targeting the GH/IGF-1 axis with novel, small molecule inhibitors
Sammanfattning : The growth hormone (GH) / insulin-like growth factor (IGF) family of ligands, binding proteins and receptors play multiple roles in cell growth, metabolism and development. In addition, numerous studies have demonstrated the pathophysiological importance of the GH/IGF-1 axis. LÄS MER
24. Prostate cancer and bone cell interactions : implications for metastatic growth and therapy
Sammanfattning : The skeleton is the most common site of prostate cancer bone metastasis, and at present, there are no curable treatments for these patients. To further understand what stimulates tumor cell growth in the bone microenvironment and to find suitable therapies, reliable model systems are needed. LÄS MER
25. Immune reconstitution after allogeneic hematopoietic stem cell transplantation
Sammanfattning : After treatment with allogeneic hernatopoietic stem cell transplantation (HSCT) the patient suffers from a deficient immune system for at least 12 months or longer. During this period, the patient is susceptible to infections and if the state of immune deficiency is prolonged there is an increased risk of relapse of the underlying malignancy as well as development of secondary malignancies. LÄS MER